Fused 1,3-dihydro-imidazole ring compounds
CA 2507763 A1 · Owner: Eisai R&D Management Co. Ltd. · Inventors: Uehara, Taisuke; Yoshikawa, Seiji; Clark, Richard
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A novel compound having excellent DPPIV inhibitory activity. It is a compound represented by the general formula (I) (wherein T1 means an optionally substituted, mono- or bicyclic, 4- to 12-membered heterocycle containing one or two nitrogen atoms therein; the structure shown by (II) means a double bond or single bond; X3 means oxygen or sulfur; X1 means optionally substituted C2- 6 alkynyl, etc.; Z1 means nitrogen or -CR3=; Z2 and Z3 each independently means nitrogen, -CR1=, carbonyl, or -NR2-; and R1 R2, R3, and X2 each , independently means optionally substituted C1-6 alkyl etc.), a salt thereof, or a hydrate of either.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 2, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 2, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 2, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.